Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index; 7 of the 85 sources its claims cite were checked for support.

Mechanisms of resistance to EGFR-targeted drugs: lung cancer

Open access
Morgillo, Floriana, Della Corte, Carminia Maria, Fasano, Morena, Ciardiello, Fortunato · 2016 · ESMO Open

Abstract

Despite the improvement in clinical outcomes derived by the introduction of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumours harbour EGFR-activating mutations, prognosis remains unfavourable because of the occurrence of either intrinsic or acquired resistance. We reviewed the published literature and abstracts of oral and poster presentations from international conferences addressing EGFR-TKIs resistance mechanisms discovered in preclinical models and in patients with NSCLC. The molecular heterogeneity of lung cancer has several implications in terms of possible mechanisms of either intrinsic or acquired resistance to EGFR-targeted inhibitors. Several mechanisms of resistance have been described to EGFR-TKIs, such as the occurrence of secondary mutation (T790M, C797S), the activation of alternative signalling (Met, HGF, AXL, Hh, IGF-1R), the aberrance of the downstream pathways (AKT mutations, loss of PTEN), the impairment of the EGFR-TKIs-mediated apoptosis pathway (BCL2-like 11/BIM deletion polymorphism) and histological transformation. Although some of the mechanisms of resistance have been identified, much additional information is needed to understand and overcome resistance to EGFR-TKI agents. The majority of resistance mechanisms described are the result of a selection of pre-existing clones; thus, studies on the mechanisms by which subclonal alterations have an impact on tumour biology and influence cancer progression are extremely important in order to define the best treatment strategy.

Overview

CoChat Summary

TL;DR

This review summarizes intrinsic and acquired mechanisms of resistance to EGFR-targeted drugs in non-small cell lung cancer (NSCLC), including secondary EGFR mutations, alternative pathway activation, downstream pathway alterations, apoptosis impairment, and histological transformation. It emphasizes that resistance often reflects selection of pre-existing subclones and that further work is needed to define optimal treatment after progression.

Key findings

  • The major acquired resistance mechanism to first-generation EGFR-TKIs is the exon 20 T790M substitution, accounting for about half of cases; third-generation EGFR-TKIs such as AZD9291 can be followed by the tertiary C797S mutation, which confers cross-resistance to all third-generation inhibitors.
  • In 15 patients with resistance to AZD9291 analysed by next-generation sequencing of cell-free DNA, distinct EGFR genotypes were acquired C797S together with T790M in 40%, T790M without C797S in 33%, and loss of T790M without C797S in 27%.
  • Alternative pathway activation is the second most common resistance mechanism; MET amplification accounts for 5–20% of acquired resistance causes, while ErbB2 amplification was responsible for acquired resistance in 12% of cases.
  • Exon 20 insertions occur in 1–10% of all EGFR mutations and are the most important frequent drug-resistant EGFR mutations; BIM deletion polymorphisms or low-to-intermediate BIM mRNA levels are associated with reduced clinical efficacy of EGFR-TKIs.

Methods

  • Narrative review of peer-reviewed publications listed in PubMed since the discovery of EGFR-activating mutations in 2004, plus oral and poster abstracts from ASCO and ESMO from 2010 to 2015.
  • Search strategy combined keywords for “NSCLC,” “EGFR mutations,” and “resistance”; articles or abstracts in languages other than English were excluded.
  • The review synthesizes preclinical models and patient data, including phase III trial results, clinical definitions/subtyping of acquired resistance, and molecular mechanisms such as secondary mutations, phenotypic transformation, and alternative pathway activation.

Limitations

  • The paper states that much additional information is needed to understand and overcome resistance to EGFR-TKI agents, that the optimum treatment after disease progression is not yet clear, and that the choice of best first-line EGFR-TKI remains debated.
  • The paper notes that the Jackman clinical definition of acquired resistance needed further clinical validation, that the most informative method to define MET amplification is not established, and that serial tumour sampling to monitor clonal evolution poses practical challenges and is not standard practice.
  • Evident from the text: this is a narrative review rather than a systematic review or meta-analysis, with selection limited to English-language PubMed publications and ASCO/ESMO abstracts from 2010–2015, so the synthesis may be subject to selection and publication biases.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1136/esmoopen-2016-000060

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Schematic representation of main EGFR-TKIs resistance mechanisms. Resistance to EGFR-TKIs can occur through different mechanisms either intrinsic or acquired. Known mechanisms are secondary resistance mutations occurring in the ATP-binding domain (such as T790M and C797S), mutation or amplification of bypass signallings (such as AXL, Hh, ERBb2, CRIPTO, etc), activating mutations in the downstream pathways (PI3K, AKT, MEK, RAF), low levels of mRNA or polymorphisms of the pro-apoptotic protein BIM, induction of a transcription programme for EMT and phenotypical changes, or induction of elevated tumour PD-L1 levels. EGFR, epidermal growth factor receptor; EMT, epithelial-to-mesenchymal transition; mRNA, messenger RNA; PD-1, programmed death receptor-1; PD-L1, programmed death ligand-1; TKI, tyrosine kinase inhibitor.
Figure 1 Schematic representation of main EGFR-TKIs resistance mechanisms. Resistance to EGFR-TKIs can occur through different mechanisms either intrinsic or acquired. Known mechanisms are secondary resistance mutations occurring in the ATP-binding domain (such as T790M and C797S), mutation or amplification of bypass signallings (such as AXL, Hh, ERBb2, CRIPTO, etc), activating mutations in the downstream pathways (PI3K, AKT, MEK, RAF), low levels of mRNA or polymorphisms of the pro-apoptotic protein BIM, induction of a transcription programme for EMT and phenotypical changes, or induction of elevated tumour PD-L1 levels. EGFR, epidermal growth factor receptor; EMT, epithelial-to-mesenchymal transition; mRNA, messenger RNA; PD-1, programmed death receptor-1; PD-L1, programmed death ligand-1; TKI, tyrosine kinase inhibitor.CC BY-NC · PubMed Central

Verification

Claims the paper makes

5 Valid · 0 Not valid · 52 Not checked · 10 Own results and interpretations

20 more claims

Create a free account to see all 67 claims and to verify the 78 references still open.

See all claims — free account
  • It may state two separate claims as one. 39
  • Probably not a substantial claim. 5

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 58 references

Research works printed but not linked: 1

  1. Oxnard, 2015, Mechanisms of acquired resistance to AZD9291 in EGFR T790M positive lung cancer, J Thorac Oncol, 10, ORAL17.07

Cited by

See all 476

Metadata

Authors
Morgillo, F., Della Corte, C. M., Fasano, M., & Ciardiello, F.
Affiliations
University of Campania "Luigi Vanvitelli" (IT)
Corresponding author
Morgillo, Floriana
Venue
ESMO Open
Publisher
Elsevier BV
Published
2016
Volume
1
Issue
3
Pages
e000060
ISSN
2059-7029 (ISSN-L)
OpenAlex
W2352491315
Cited by
476
References
58
Citations by year
2026: 32 · 2025: 52 · 2024: 49 · 2023: 45 · 2022: 46 · 2021: 49 · 2020: 69 · 2019: 53 · 2018: 47 · 2017: 33
FWCI
7.69
Type
journal article
Language
en
Open access
Licence
Locations
  • ESMO Open (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion, public-domain)
Funders
Associazione Italiana per la Ricerca sul Cancro (MFAG 2013-N.14392)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords
EGFR tyrosine kinase inhibitors, drug resistance, non-small cell lung cancer, EGFR mutation, T790M mutation, C797S mutation, MET, hepatocyte growth factor, AXL, Hedgehog signaling, IGF-1 receptor, AKT mutations, PTEN loss, apoptosis, histologic transformation, clonal selection, subclonal heterogeneity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mechanisms of resistance to EGFR-targeted drugs: lung cancer. https://app.cochat.ai/papers/10.1136/esmoopen-2016-000060
The paper
Morgillo, F., Della Corte, C. M., Fasano, M., & Ciardiello, F. (2016). Mechanisms of resistance to EGFR-targeted drugs: lung cancer. ESMO Open. https://doi.org/10.1136/esmoopen-2016-000060

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.